Patritumab Deruxtecan(HER3-DXd),一种靶向人表皮生长因子受体3的抗体药物偶联物,用于既往经治的人表皮生长因子受体3表达转移性乳腺癌患者:一项多中心I/II期试验
该多中心I/II期研究评估了HER3靶向抗体药物偶联物HER3-DXd在既往经治的HER3表达转移性乳腺癌患者中的安全性和疗效。182例患者接受HER3-DXd治疗,在激素受体阳性/HER2阴性、三阴性及HER2阳性亚型中均观察到客观缓解,中位无进展生存期分别为7.4、5.5和11.0个月。HER3-DXd显示出可控的安全性和持久的疗效,作者认为值得进一步评估。
要点
- HR+/HER2阴性乳腺癌患者客观缓解率为30.1%,中位无进展生存期7.4个月。
- 三阴性乳腺癌患者客观缓解率为22.6%,中位无进展生存期5.5个月。
- HER2阳性乳腺癌患者客观缓解率为42.9%,中位无进展生存期11.0个月。
核心结论
- HER3-DXd在既往经治的HER3表达转移性乳腺癌各临床亚型中显示出可控的安全性和持久的疗效,这些数据值得进一步评估。
研究设计与样本
- 多中心I/II期试验(U31402-A-J101),纳入既往治疗后疾病进展的成人患者,剂量递增部分主要目标为确定最大耐受剂量和推荐扩展剂量(RDE),并在剂量扩展部分评估RDE的安全性和疗效。
- 182例入组患者接受了至少1剂HER3-DXd,既往针对晚期疾病的中位治疗线数为5线。
主要发现
- 激素受体阳性(HR+)/人表皮生长因子受体2阴性(HER2阴性)乳腺癌患者(n=113)客观缓解率为30.1%,中位无进展生存期为7.4个月。
- 三阴性乳腺癌患者(n=53)客观缓解率为22.6%,中位无进展生存期为5.5个月。
- HER2阳性乳腺癌患者(n=14)客观缓解率为42.9%,中位无进展生存期为11.0个月。
- 在HER3高表达和HER3低表达膜表达的肿瘤中均观察到客观缓解。
- 剂量扩展阶段,胃肠道和血液学毒性是最常见的治疗中出现的不良事件(TEAE),71.4%的患者发生≥3级TEAE,9.9%的患者因TEAE终止治疗,发生3例3级和1例5级治疗相关间质性肺病事件。
关键数值与推荐
- 剂量递增、剂量探索和剂量扩展部分患者接受HER3-DXd 1.6-8.0 mg/kg静脉给药,每3周一次,或两种替代给药方案之一。
- 剂量选择期间观察到的剂量限制性毒性为血小板计数降低和转氨酶升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is being evaluated as a novel treatment in HER3-expressing advanced breast cancer in the U31402-A-J101 study. METHODS: Adults with disease progression on previous therapies were eligible. Patients in the dose-escalation, dose-finding, and dose-expansion parts received HER3-DXd 1.6-8.0 mg/kg intravenously once every 3 weeks or one of two alternative dosing regimens. In the dose-escalation part, the primary objectives were to determine the maximum tolerated dose and recommended dose for expansion (RDE). The safety and efficacy of the RDE were assessed during dose expansion. RESULTS: One hundred eighty-two enrolled patients received ≥1 dose of HER3-DXd. Patients had a median of five previous therapies for advanced disease. Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer (n = 113; objective response rate [ORR], 30.1%; median progression-free survival [mPFS], 7.4 months), triple-negative breast cancer (n = 53; ORR, 22.6%; mPFS, 5.5 months), and HER2-positive breast cancer (n = 14; ORR, 42.9%; mPFS, 11.0 months). Objective responses were observed in cancers with HER3-high and HER3-low membrane expression. Dose-limiting toxicities observed during dose selection were decreased platelet count and elevated aminotransferases. In dose expansion, GI and hematologic toxicities were the most common treatment-emergent adverse events (TEAEs) observed. Grade ≥3 TEAEs were observed in 71.4% of patients, and 9.9% discontinued treatment because of TEAEs. Three grade 3 and one grade 5 treatment-related interstitial lung disease events occurred. CONCLUSION: HER3-DXd demonstrated a manageable safety profile and durable efficacy in heavily pretreated patients across clinical subtypes. These data warrant further evaluation of HER3-DXd in patients with HER3-expressing metastatic breast cancer.
引用
- Krop IE, Masuda N, Mukohara T, et al. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial. J Clin Oncol. 2023. PMID: 37801674. doi:10.1200/JCO.23.00882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。